Physician profile
Matthew Collin
NPI 1063099364
$1,462.86
in general payments reported to CMS, 2019-2025
12 companies · $558 in 2025
The $558 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $100 · 2024: $805 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.86 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $302.88 | 2024-2025 | Fintepla, Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $224.24 | 2024-2025 | Ultomiris |
| Csl Behring | $206.90 | 2024 | Hizentra, Kcentra |
| Novartis Pharmaceuticals Corporation | $127.25 | 2025 | |
| Genzyme Corporation | $124.76 | 2024 | |
| Argenx US, INC. | $115.20 | 2024 | Vyvgart Hytrulo |
| Celgene Corporation | $100.13 | 2023 | |
| Vanda Pharmaceuticals INC. | $96.94 | 2025 | Ponvory |
| Emd Serono, INC. | $69.54 | 2025 | |
| Biogen, INC. | $48.83 | 2025 | Skyclarys, Vumerity |
| Genentech USA, INC. | $23.89 | 2025 | Ocrevus Zunovo |
| Grifols USA, LLC | $22.30 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Collin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.